|Slideshows|January 6, 2020

5 Domains of Functional Assessment for Disability Evaluation

Author(s)Group for the Advancement of Psychiatry, Barbara Long, MD, PhD, FABPN, Andrew O. Brown, MD

Problems with any one of these domains can disrupt an individual’s capacity to sustain work capacity.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Data Supports Potential of Negative Allosteric Modulators for Anxiety and Fear-Related Disorders

ByJessica Walters

February 4th 2026

Pressure Is a Privilege: Being Clinicians in Complex Situations

BySusan J. Noonan, MD, MPH

January 26th 2026

Stress in Sports: What It Really Means and How to Discuss With Athletes

ByKennedy Collins, MS,Sara Tobias, MS,Mena Mirhom, MD, FAPA

January 7th 2026

Fasedienol for Social Anxiety Disorder Does Not Demonstrate Significant Improvement in Phase 3 Study

ByJessica Walters

December 17th 2025

Psychedelic PSX-001 for Generalized Anxiety Disorder: A Conversation With Lou Barbato, MD

ByLeah Kuntz,Lou Barbato, MD

December 4th 2025

Latest CME

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

5 Domains of Functional Assessment for Disability Evaluation

Newsletter

Related Content

Data Supports Potential of Negative Allosteric Modulators for Anxiety and Fear-Related Disorders

Pressure Is a Privilege: Being Clinicians in Complex Situations

Stress in Sports: What It Really Means and How to Discuss With Athletes

Fasedienol for Social Anxiety Disorder Does Not Demonstrate Significant Improvement in Phase 3 Study

Psychedelic PSX-001 for Generalized Anxiety Disorder: A Conversation With Lou Barbato, MD

Latest CME

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Trending on Psychiatric Times

Depression and Long COVID Outcomes in Women: New Data Analysis

Patterns of Propensity: A Review of Heinrichs’ How Psychiatrists Make Decisions

Investigational Psilocybin for PTSD and Ongoing Trials

In Memoriam: Elise Snyder, MD, A Legacy of Mentoring to Psychotherapists in China

Extension of Expanded Access Program for Zervimesine to Treat Dementia With Lewy Bodies